Article

Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression

2022-06-13

Abstract excerpt

<h4>Background: </h4> Pancreatic ductal adenocarcinoma (PDA) has a poor prognosis largely due to its therapeutic resistance. Inactivation of vitamin D/vitamin D receptor (VDR) signaling contributes to the malignant phenotype of PDA, and altered expression of oncoprotein mucin 1 (MUC1) is involved in drug resistance of cancer cells. In the present study, we determined whether vitamin D/VDR signaling regulates the e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf2813dc-520f-5775-96fd-0065b06c6dcb
DOI: 10.21203/rs.3.rs-1723818/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expressionDOI 10.21203/rs.3.rs-1723818/v1Read

Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell StemnessSemantic proximity Read

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.Semantic proximity Read

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.Semantic proximity Read

Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic CancerSemantic proximity Read

Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancerSemantic proximity Read

Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Semantic proximity Read

Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada.Semantic proximity Read

S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabineSemantic proximity Read

Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin ASemantic proximity Read

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read

Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cellsSemantic proximity Read

Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT 1 to miR1207Semantic proximity Read